Montmorillonit jako nośnik leku

• Autorzy: Rapacz-Kmita A.

Warianty tytułu

EN

Montmorillonite as a drug carrier

• Języki publikacji: PL EN

Abstrakty

PL

Zastosowanie minerałów ilastych, a w szczególności montmorillonitu, dla celów medycznych, sięga czasów prehistorycznych. Szczególne własności tej grupy minerałów, ich powszechność, niski koszt, zdolności wymiany jonowej, zdolności absorpcyjne, inertność w kontakcie z tkankami ludzkimi oraz budowa sprawiły, iż znalazły się one w kręgu zainteresowania jako potencjalne nośniki substancji leczniczych w systemach kontrolowanego dostarczania leków. Obecnie, minerały ilaste, a w szczególności montmorillonit, są stosowane na szeroką skalę w preparatach farmaceutycznych, jako substancje pomocnicze oraz składniki aktywne. Możliwość interkalacji związków organicznych, jakimi są leki, pomiędzy warstwy montmorillonitu, stwarza nowe możliwości wykorzystania tego minerału. W systemach kontrolowanego dostarczania leków kluczowym elementem jest zastosowanie odpowiedniego materiału nośnika, który przede wszystkim musi charakteryzować się brakiem toksyczności, biokompatybilnością, ale także spełniać odpowiednie wymogi technologiczne, jak np.: duża wydajność produkcji oraz stabilność w środowisku żywego organizmu. Zastosowanie montmorillonitu jako nośnika leku może przyczynić się do uzyskania kontrolowanego i przedłużonego uwalniania leku, ale także do eliminacji skutków ubocznych działania leku na organizm. Dzięki słabym wiązaniom van der Waalsa i wodorowym istniejącym pomiędzy warstwami montmorillonitu, możliwe jest zainterkalowanie cząstek leku pomiędzy warstwy minerału i tym samym utworzenie nietrwałego połączenia z farmaceutykiem. Zainteresowanie minerałami ilastymi w systemach kontrolowanego dostarczania leków potwierdza systematycznie rosnąca liczba publikacji powiązanych z tą tematyką. Praca stanowi podsumowanie dotychczasowej wiedzy na temat wykorzystania minerałów ilastych, a w szczególności montmorillonitu, w zastosowaniach medycznych.

EN

The use of clay minerals for medical applications dates back to prehistoric times. Specific properties of this group of minerals, their universality, low cost, ability to ion exchange, absorption capacity, inertness in contact with human tissues as well as their structure, caused that they had been included in the area of interest as potential carriers of medicinal substances in controlled drug delivery systems. At present, clay minerals, in particular montmorillonite, are extensively used in pharmaceutical formulations both as excipients and the active components. The possibility of intercalation of organic compounds, which are drugs among the others, between the layers of montmorillonite, creates new possibilities for the use of this mineral. In the controlled drug delivery systems, the key element is the use of a suitable material for carrier, which primarily must be characterized by a lack of toxicity, good biocompatibility, but also is expected to meet the relevant technological requirements, such as: high efficiency of production and stability in a living organism. The use of a montmorillonite carrier may help to achieve a controlled and sustained release of the drug but also to eliminate the side effects of the drug on the human’s body. Due to the weak van der Waals and hydrogen bonds which exist between montmorillonite layers, it is possible to intercalate the drug particles between the layers and thus forming the impermanent connection to the pharmaceutical. Interest in clay minerals in controlled drug delivery systems is confirmed by the steadily growing number of publications related to this topic. The work is a summary of current knowledge on the use of clay minerals, particularly montmorillonite, in medical applications

Słowa kluczowe

PL

surowce ilaste; montmorillonit; nośnik leku; systemy dostarczania leków

EN

clays; montmorillonite; drug carrier; drug delivery systems

• Wydawca: Polish Society for Biomaterials in Cracow
• Czasopismo: Engineering of Biomaterials
• Rocznik: 2017
• Tom: Vol. 20, no. 139
• Strony: 8--17
• Opis fizyczny: Bibliogr. 47 poz., rys., tab., wykr.

Twórcy

autor

Rapacz-Kmita A.

• AGH Akademia Górniczo-Hutnicza, Wydział Inżynierii Materiałowej i Ceramiki, al. Mickiewicza 30, 30-059 Kraków

Bibliografia

• [1] Carretero M.I.: Clay minerals and their beneficial effects upon human health. A review. Applied Clay Science 21 (2002) 155-163.
• [2] Carretero M.I., Gomes C.S.F., Tateo F.: Clay and human health. Handbook of Clay Science, Elsevier 2006.
• [3] Carretero M.I., Pozo M.: Clay and non-clay minerals in the pharmaceutical industry part I. Excipients and medical applications. Applied Clay Science 46 (2009) 73-80.
• [4] Lagaly G., Ogawa M., Dekany I.: Clay mineral-organic interactions. Handbook of Clay Science, Elsevier 2006.
• [5] Aguzzi C., Cerezo P., Viseras C., Caramella C.: Use of clays as drug delivery systems: possibilities and limitations. Applied Clay Science 36 (2007) 22-36.
• [6] Wu L., Liao L., Lv G.: Influence of interlayer cations on organic intercalation of montmorillonite. Journal of Colloid and Interface Science 454 (2015) 1-7.
• [7] Carretero M.I., Lagaly G.: Clays and health. An introduction. Applied Clay Science 36 (2007) 1-3.
• [8] Hładoń T.: Layer silicates as carriers of some active pharmaceutical substances. Mineralogia Polonica 19, 2 (1988) 111-115.
• [9] Viseras C., Lopez-Galindo A.: Pharmaceutical applications of some spanish clays (sepiolite, palygorskite, entonite): some preformulation studies. Applied Clay Science 14 (1999) 69-82.
• [10] Lagaly G., Reese M., Abend S.: Smectites as colloidal stabilizers of emulsions I. Preparation and properties of emulsions with smectites and nonionic surfactants. Applied Clay Science 14 (1999) 83-103.
• [11] López-Galindo A., Viseras C.: Pharmaceutical and cosmetic applications of clays. In Clay Surfaces: fundamentals and applications. Elsevier, Amsterdam 2004.
• [12] Viseras C., Aguzzi A., Cezaro P., López-Galindo A.: Uses of clay minerals in semisolid health care and therapeutic products. Applied Clay Science 36 (2007) 37-50.
• [13] Murray H.H.: Traditional and new applications for kaolin, smectite, and palygorskite: a general overview. Applied Clay Science 17 (2000) 207-221.
• [14] Konta J.: Clay and man: Clay raw materials in the service of man. Applied Clay Science 10 (1995) 275-335.
• [15] Anand V., Kandarapu R., Garg S.: Ion-exchange resins: carrying drug delivery forward. Drug Discovery Today 6, 17 (2001) 905-914.
• [16] Browne J.E., Feldkamp J.R., White J.L., Hem S.L.: Characterization and adsorptive properties of pharmaceutical grade clays. Journal of Pharmaceutical Sciences 69, 7 (1980) 816-823.
• [17] Legaly G.: Pesticide-clay interactions and formulations. Applied Clay Science 18 (2001) 205-209.
• [18] Kevadiya B.D., Bajaj H.C.: The layered silicate, montmorillonite (MMT) as a drug delivery carrier, Key Engineering Materials 571 (2013) 111-132.
• [19] Plaizier-Vercammen J.A.: Investigation of the bioavailability of codeine from a cation ion-exchange sulfonic acid: effect of parameters. International Journal of Pharmaceutics 85 (1992) 45-50.
• [20] Yang J.-H., Lee J.-H., Ryu H.-J, Elzatahry A.A., Alothman Z.A., Choy J.-H.: Drug-clay nanohybrids as sustained delivery systems. Applied Clay Science 130 (2016) 20-32.
• [21] de Sousa Rodrigues L.A., Figueiras A., Veiga F., de Freitas R.M., Nunes L.C.C., da Silva Filho E.C., da Silva Leite C.M.: The systems containing clays and clay minerals from modified drug release: A review. Colloids Surfaces B Biointerfaces 103 (2013) 642-651.
• [22] Gibaldi M., Desai A., Lee M.: Pharmacokinetic considerations for drug delivery. Gibaldi’s Drug Delivery Systems in Pharmaceutical Care. American Society of Health-System Pharmacists 2007.
• [23] Ding X., Alani A.W.G., Robinson J.R.: Extended-release and targeted drug delivery systems. Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins 2006.
• [24] Arcos D., Vallet-Regi M.: Bioceramics for drug delivery. Acta Materialia 61 (2013) 890-911.
• [25] Viseras C., Cerezo P., Sanchez R., Salcedo I., Aguzzi C.: Current challenges in clay minerals for drug delivery. Applied Clay Science 48 (2010) 291-295.
• [26] Rao T., Vidhyadhara S.: Formulation and in vitro evaluation of indomethacin microcapsules. Sadguru Publications Udaipur 10 (2012) 1-8.
• [27] Dupeyrón D., Kawakami M., Ferreira A., Cáceras-Vélez P., Rieumont J., Azevedo R., Carvalho J.: Design of indomethacin- -loaded nanoparticles: effect of polymer matrix and surfactant. International Journal of Nanomedicine 8 (2013) 3467-3477.
• [28] Lin F., Lee Y., Jian J., Wong J., Shieh M., Wang C.: A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 23 (2002) 1981-1987.
• [29] Zheng J.P., Luan L., Wang H.Y., Xi L.F., Yao K.D.: Study on ibuprofen/montmorillonite intercalation composites as drug release system. Applied Clay Science 36 (2007) 297-301.
• [30] Tabak A., Yilmaz N., Eren E., Caglar B., Afsin B., Sarihan A.: Structural analysis of naproxen-intercalated bentonite (Unye). Chemical Engineering Journal 174 (2011) 281-288.
• [31] Kaur M., Datta M.: Diclofenac sodium adsorption onto montmorillonite: adsorption equilibrium studies and drug release kinetics. Adsorption Science & Technology 32, 5 (2014) 365-388.
• [32] Park J.K., Bin Choy Y., Oh J.M., Kim J.Y., Hwang S., Choy J.H.: Controlled release of donapenzil intercalated in smectite clays. International Journal of Pharmaceutics 359 (2008) 198-204.
• [33] Chen Y., Zhou A., Liu B., Liang J.: Tramadol hydrochloride/ montmorillonite composite: preparation and controlled drug release. Applied Clay Science 49 (2010) 108-112.
• [34] Joshi G.V., Kevadiya B.D., Patel H.A., Bajaj H.C., Jasra R.V.: Montmorillonite as a drug delivery system: Intercalation and in vitro release of timolol maleate. International Journal of Pharmaceutics 374 (2009) 53-57.
• [35] Datta M.: Organoclay Pluronic F68 – Montmorillonite, as a sustained release drug delivery vehicle for propranolol hydrochloride. European Chemical Bulletin 3, 6 (2014) 593-604.
• [36] Lakshmi M.S., Sriranjani M., Bakrudeen H.B., Kannan A.S., Mandal A.B., Reddy B.S.R.: Carvedilol/montmorillonite: processing, characterization and release studies. Applied Clay Science 48 (2010) 589-593.
• [37] Jain S., Datta M.: Naturally occuring clay, montmorillonite, as a drug delivery vehicle for in vitro extended release of venlafaxine hydrochlorid., European Chemical Bulletin 3, 7 (2014) 672-681.
• [38] Pongjanyakul T., Khunawattanakul W., Puttipipatkhachorn S.: Physicochemical characterizations and release studies of nicotine- -magnesium aluminum silicate complexes. Applied Clay Science 44 (2009) 242-250.
• [39] Parolo M.E., Savini M.C., Valles J.M., Baschini M.T., Avena M.J.: Tetracycline adsorption on montmorillonite: pH and ionic strength effects. Applied Clay Science 40 (2008) 179-186.
• [40] Meng N., Zhou N.L., Zhang S.Q., Shen J.: Controlled release and antibacterial activity chlorhexidine acetate (CA) intercalated in montmorillonite. International Journal of Pharmaceutics 382 (2009) 45-49.
• [41] Parolo M.E., Avena M.J., Pettinari G., Zajonkovsky I., Valles J.M., Baschini M.T.: Antimicrobial properties of tetracycline and minocycline- montmorillonites. Applied Clay Science 49 (2010) 194-199.
• [42] Saha K., Butola B.S., Joshi M.: Synthesis and characterization of chlorhexidine acetate drug-montmorillonite intercalates for antibacterial applications. Applied Clay Science 101 (2014) 477-483.
• [43] Rapacz-Kmita A., Stodolak-Zych E., Ziąbka M., Różycka A., Dudek M.: Instrumental characterization of the smectite clay-gentamicin hybrids. Bulletin of Materials Science 38, 4 (2015) 1069-1078.
• [44] Calabrese I., Cavallaro G., Scialabba C., Licciardi M., Merli M., Sciascia L., Turco Liveri M.L.: Montmorillonite nanodevices for the colon metronidazole delivery. International Journal of Pharmaceutics 457 (2013) 224-236.
• [45] Joshi G.V., Patel H.A., Kevadiya B.D., Bajaj H.C.: Montmorillonite intercalated with vitamin B1 as drug carrier. Applied Clay Science 45 (2009) 248-253.
• [46] Ghebaur A., Garea S.A., Iovu H.: The influence of inorganic host type in the drug-layered silicate biosystems. UPB Scientific Bulletin, Series B: Chemistry and Materials Science 73, 3 (2011) 169-176.
• [47] Golubeva O.Y., Pavlova S.V., Yakovlev A.V.: Adsorption and in vitro release of vitamin B1 by synthetic nanoclays with montmorillonite structure. Applied Clay Science 112-113 (2015) 10-16

Uwagi

Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę (zadania 2017).